In March 2024, Neuronetics received FDA clearance for its NeuroStar TMS system as a first-line, adjunctive treatment for major depressive disorder in adolescents aged 15 to 21, according to the company's own financial disclosure.
Neuronetics has also reported analyses of real-world outcomes in adolescents and young adults from its TrakStar database. Those figures are manufacturer-reported and have been criticized by some clinicians for limited adverse-event data.
This is an older item retained for context. Families should discuss adolescent TMS with a qualified child and adolescent psychiatrist.
Source
Reporting based on coverage from Neuronetics (via Nasdaq/GlobeNewswire). This article is editorial summary intended for general information; it is not medical advice.
